Tag: KDC-MN-066

  • Meldonium (Mildronate)

    Carnitine biosynthesis inhibitor

    A Latvian-developed carnitine biosynthesis inhibitor used clinically for ischemic heart disease, banned by WADA in 2016 after high-profile athlete cases.

    Abstract

    Meldonium (Mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; CAS 76144-81-5; molecular formula C6H14N2O2; molecular weight 146.19) is a synthetic structural analog of gamma-butyrobetaine, the precursor of L-carnitine, developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. The compound competitively inhibits gamma-butyrobetaine hydroxylase, reducing endogenous carnitine biosynthesis and shifting cardiac and skeletal muscle metabolism from fatty acid oxidation toward glucose oxidation. The metabolic shift is theoretically protective under ischemic conditions where fatty acid oxidation generates increased reactive oxygen species. Meldonium is approved in Latvia, Russia, and several former Soviet states for ischemic heart disease, chronic heart failure, and cognitive symptoms of cerebrovascular insufficiency. The compound was added to the WADA prohibited list in 2016 after widespread use in elite athletes; the Maria Sharapova case is the most prominent. Pharmacokinetics: plasma half-life 3 to 6 hours; oral bioavailability 78 percent; renally excreted.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.